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Familial breast cancer was first recognized in the
Roman medical literature of 100 AD [1]. The first
documentation of familial clustering of breast cancer
in modern times was published by Broca, who reported
10 cases of breast cancer in 4 generations of his wife’s
family [2]. In the middle of the nineteen nineties it was
proven at the molecular level that a substantial number
of breast and ovarian cancers has hereditary
monogenic aetiology [3, 4]. Evaluation of frequency
of pedigree-clinical signs characteristic for strong
aggregations of breast/ovarian cancers among
consecutive cases of cancers of these organs as well
as analyses of cancer incidence in monozygotic twins
indicate that about 30% of breast and ovarian cancers
develop because of a strong genetic predisposition [5].
In other breast/ovarian cancers the significance of
genetic factors was underestimated. However, recently
it has been possible to show the characteristic
constitutional background influencing development of
cancer also in patients with sporadic neoplasms.
Therefore now scientists think that in almost all patients
with cancer a certain genetic background should be
detectable, although influencing cancer risk to 
a various degree. Genetic abnormalities strongly
related to cancer are called high risk changes (genes)
and abnormalities influencing cancer development to
a lower degree are called moderate risk changes
(genes). Most frequently strong genetic predisposition
to breast/ovarian cancers are related to mutations in
the BRCA1 and BRCA2 genes and most often it
appears as syndromes of hereditary breast cancer –
site-specific (HBC-ss), hereditary breast-ovarian cancer
(HBOC) and hereditary ovarian cancer (HOC).
In family members of families with HBC-ss syndrome
only breast cancers but not ovarian cancers are
observed. In HBOC syndrome families both breast and
ovarian cancers are diagnosed, and in HOC syndrome
only ovarian but not breast cancers are detected.
Operational clinical-pedigree criteria which we use in
order to diagnose “definitively” or “with high probability”
the discussed syndromes are summarized in Table 1. In
the vast majority of cancer cases related to moderate
risk genes family history is negative. HBC-ss, HBOC and
HOC syndromes are clinically and molecularly
heterogeneous. Mutations in the BRCA1 and BRCA2
genes are the most frequent cause of these syndromes.
B BR RC CA A1 1 s sy yn nd dr ro om me e
In this syndrome women carry a germline mutation
in the BRCA1 gene. Carriers of a BRCA1 mutation have
approximately 50-80% lifetime risk of breast cancer and
40% risk of ovarian cancer [7]. We estimate that these
risks are 66% for breast cancer and 44% for ovarian
T Ta ab bl le e   1 1. .   Pedigree-clinical diagnostic criteria of HBC-ss, HBOC and
HOC syndromes [6]
N Nu um mb be er r   o of f   b br re ea as st t   o or r   o ov va ar ri ia an n   c ca an nc ce er r   c ca as se es s   i in n   f fa am mi il ly y: :
A – 3 (definitive diagnosis)
1) At least 3 relatives affected with breast or ovarian cancer 
diagnosed at any age
B – 2 (highly probable diagnosis)
1) 2 breast or ovarian cancer cases among first degree relatives 
(or second degree through male line)
2) 1 breast cancer and 1 ovarian cancer diagnosed at any age
among first degree relatives (or second degree through male line)
C – 1 (highly probable diagnosis)
1) Breast cancer diagnosed below 40 years of age
2) Bilateral breast cancer
3) Medullary or atypical medullary breast cancer
4) Breast and ovarian cancer in the same person
5) Breast cancer in maleH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 89
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T Ta ab bl le e   2 2. .   Risk of breast and ovarian cancer in BRCA1 mutation carriers in Poland [8]
A A. .   C Cu um mu ul la at te ed d   r ri is sk k   o of f   b br re ea as st t   c ca an nc ce er r
Age <30 40 50 60 70 75
Cumulated risk (%) 1.6 6.5 30 40.5 50.5 66
B B. .   C Cu um mu ul la at te ed d   r ri is sk k   o of f   o ov va ar ri ia an n   c ca an nc ce er r
Age <30 40 50 60 70 75
Cumulated risk (%) 1 3.5 12 30 41 44
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F Fi ig gu ur re e   1 1. .   Family with HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation
cancer in the Polish population (Table 2). Both risks
appear to be dependent on the type and localization
of the mutation [8-10]. Our findings suggest that the
risk of breast cancer in women with 5382insC is two
times higher than in women with 4153delA. 
Incomplete penetrance of BRCA1 suggests that
other factors, genetic and non-genetic modifiers, are
important in carcinogenesis in the mutation carriers.
The risk of ovarian cancer is modified by VNTR locus
for HRAS 1 and is increased 2-fold in BRCA1 carriers
harbouring one or two rare alleles of HRAS 1 [11]. We
reported that the 135G>C variant in the RAD51 gene
is strongly protective (OR =0.5) against both ovarian
and breast cancer [12,13].
Carriers of a BRCA1 mutation are also at about 10%
lifetime risk of fallopian tube and peritoneal cancers [14].
These data about the frequency of ovarian cancer in
BRCA1 carriers appear to reflect the combined frequency
of ovarian, fallopian tube and peritoneal cancers, because
these tumours were diagnosed as ovarian cancers in the
past, and because they share similar morphology and
cause elevated levels of the marker CA 125.
The risk of cancer at other sites may be increased
in carriers of a BRCA1 mutation as well, but the
evidence is controversial and needs further studies.
Breast and ovarian cancer in BRCA1 carriers have
particular clinical characteristics. The mean age at
onset of breast cancer is about 42-45 years [15, 16]
and of ovarian cancer is about 54 years [17, 18]. 
18-32% of breast cancers are bilateral [19, 20]. These
are rapidly growing tumours: >90% of cases have G3
grade at the time of diagnosis and almost all ovarian
cancers in women with a BRCA1 mutation are
diagnosed in FIGO stage III°/IV°. Medullary, atypical
medullary, ducal and oestrogen receptor negative (ER)
breast tumours are common in BRCA1 carriers. BRCA1
mutation-positive tumours constitute about 10-15% of
all ER-breast cancers [21-23]. Most carriers of a BRCA1
mutation report a positive family history of breast or
ovarian cancer (Figure 1). However, 45% of BRCA1H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 90
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carriers report a negative family history, mainly because
of paternal inheritance and incomplete penetrance
(Figure 3) [20].
M Mo ol le ec cu ul la ar r   d di ia ag gn no os si is s   o of f   c co on ns st ti it tu ut ti io on na al l
B BR RC CA A1 1 m mu ut ta at ti io on ns s
This topic has been described in detail in the section
“BRCA1 Test”.
B BR RC CA A2 2 s sy yn nd dr ro om me e
Patients with this syndrome have a constitutional
mutation in the BRCA2 gene [24]. According to
literature data lifetime risk for BRCA2 carriers from
families with definitive HBC-ss and HBOC is estimated
at 31-56% for breast cancer and 11-27% for ovarian
cancer [10, 25-28]. Studies performed in 200 Polish
families with strong aggregation of breast and/or
ovarian cancers proved that mutations in the BRCA2
gene are rare, with a frequency of 4%. There are no
studies on cumulated cancer risk in BRCA2 mutation
carriers from the Polish population. Most BRCA2
mutations from the Polish population probably slightly
increase breast cancer risk. Studies performed in our
centre showed that in families with aggregation of
breast cancer diagnosed before the age of 50 and
stomach cancer diagnosed in males before the age of
55, frequency of BRCA2 carriers is about 10-20% [29].
BRCA2 mutations are also related to a significantly
increased although not precisely estimated risk of
ovarian cancer and cancers of the digestive tract such
as stomach, colon and pancreas in both females and
males. Studies performed in our centre showed that
BRCA2 mutations are detected with a frequency of 30%
in families without breast cancer but with aggregation
of ovarian cancer with stomach, colon or pancreatic
cancer between first and second degree relatives [30].
BRCA2 studies performed on male breast cancer
patients from the Poznañ population showed that 15%
of patients from this group are mutation carriers [31].
Breast and ovarian cancers in families with BRCA2
mutations have characteristic features. Medium age of
breast cancer is 52 and 53 in females and males,
respectively, and 62 for ovarian cancer [31, 32].
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F Fi ig gu ur re e   2 2. .   Family with fulfilled clinical-pedigree criteria “suspected
HBC-ss”. BRCA1 mutation was not detected
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F Fi ig gu ur re e   3 3. .   Patient with ovarian cancer and detected 5382insC BRCA1 mutation from family with negative family historyH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 91
M Mo ol le ec cu ul la ar r   d di ia ag gn no os si is s   o of f   B BR RC CA A2 2 m mu ut ta at ti io on ns s
Unlike for the BRCA1 gene, a founder effect for
BRCA2 mutations was not observed with significant
frequency in the Polish population [22]. It should be
noted that “de novo” mutations are rare in these
groups of genes; thus the presence of founder
mutations in BRCA2 is probable. As yet BRCA2
mutations should be diagnosed individually for each
family by full sequencing. Since the BRCA2 gene is
large – about 70 genomic kbp – the cost of
sequencing of this gene is high (around 1500 euro).
In families with a detected marker of constitutional
mutation the cost of analysis of two independently taken
blood samples allowing exclusion or confirmation of
carrier status among relatives is low – around 100 euro.
B BR RC CA AX X s sy yn nd dr ro om me e
In Poland in about 30% of families with definitively
diagnosed HBC-ss and HBOC syndromes and in
about 40% of families with HOC syndrome, BRCA1 or
BRCA2 mutations are not detected. In rare cases it is
possible to diagnose one of the rare syndromes listed
in Table 3. In these syndromes breast/ovarian cancers
are observed with higher frequency. Many groups
worldwide are trying to identify new genes causing
BRCAX syndrome.
C Cl li in ni ic ca al l   m ma an na ag ge em me en nt t   i in n   f fa am mi il li ie es s   w wi it th h
h hi ig gh h   r ri is sk k   o of f   b br re ea as st t/ /o ov va ar ri ia an n   c ca an nc ce er r
Special management should be applied for:
• carriers of mutations of high breast/ovarian cancer
Hereditary breast and ovarian cancer
T Ta ab bl le e   3 3. . Selected rare syndromes with increased risk of breast and/or ovarian cancer
D Di is se ea as se e C Cl li in ni ic ca al l   f fe ea at tu ur re es s G Ge en ne e   m mu ut ta at ti io on n/ / R Re ef fe er re en nc ce es s
I In nh he er ri it ta an nc ce e
Li-Fraumeni syndrome breast cancers, sarcomas, brain tumours, leukaemia,  p53, high penetrance,  17, 33
renal gland cancer AD
Cowden disease multifocal mucoid skin abnormalities, benign proliferative  PTEN, 34, 35
abnormalities of different organs, thyroid cancers,  AD
breast/ovarian cancers
HNPCC colon cancers, endometrial cancers, other organ cancers  MSH2, MLH1, 36
including breast and ovary AD
Peutz-Jeghers syndrome hyperpigmentation of the mouth, bowel polyps, colorectal  STK11, 37
cancers, small bowel cancers, gonadal tumours, breast cancers AD
Ruvalcaba-Myhre-Smith  macrocephaly, bowel polyps, “café-au-lait” on penis,  PTEN, 38
(Z. Bannayan-Riley-Ruvalcaba)  lymphomas, thyroid cancers, breast cancers AD
syndrome
Heterozygotic carrier status  ocular ataxia, ataxia of cerebellum and skin, hypersensitivity to  ATM 39
of “ataxia telangiectasia” gene radiation, different site neoplasm including breast/ovarian cancer
ATH gene carriers increased breast cancer risk low penetrance 6
20-40%, AD
Klinefelter syndrome gynaecomastia, cryptorchidism, extragonadal germ cell  47, XXY, 40
tumours, male breast cancer low penetrance,
<10%
Androgen receptor gene  familial male breast cancer androgen 41
mutation receptor
Constitutional translocation  increased breast cancer risk balanced  42
t(11q;22q) translocation 
t(11q;22q)
Inheritance
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risk; usually around 50% of female family members
should be included in the programme;
• all family members of families with HBC-ss, HBOC
or HOC diagnosed definitively or with high
probability according to pedigree criteria shown in
Table 1, if constitutional mutations predisposing to
cancer were not detected.
Special management concerns:
• prophylactics,
• surveillance,
• treatment.
P Pr ro op ph hy yl la ac ct ti ic cs s
Oral contraceptives
Contraindications for use of oral contraceptives (OC)
by BRCA1 carriers aged below 25 are well documented.
It was shown that OC used for 5 years by young women
increase breast cancer risk by about 35% [43]. Since in
about 50% of BRCA1 carriers family history is negative
it seems to be necessary to perform the BRCA1 test in
every young woman who wishes to use OC. OC used
by BRCA1 carriers after the age of 30 seems not to
influence breast cancer risk [43-45] but shows a 50%
reduction of ovarian cancer risk [34], so use of OC after
the age of 30 appears to be justified. As yet, there are
no verified data concerning the effects of OC in families
not related to BRCA1 mutation. However, there are
studies indicating several-fold increased breast cancer
risk in OC users from families with breast cancer
aggregation [46]; thus it seams reasonable to avoid OC
in families with HBC-ss and/or HBOC.
Hormone replacement therapy (HRT)
Prophylactic oopherectomy at the age of 35-40 is the
gold standard for BRCA1/2 carriers and corresponds with
risk reduction for both breast and ovarian cancer. It was
shown that carriers after oopherectomy, who use
oestrogen HRT, show a similar protective effect as patients
who do not use HRT [47, 48]. The influence of HRT in
carriers without prophylactic oopherectomy is not well
documented. Three-fold increased risk of breast cancer
in HRT users with positive breast cancer family history
was reported [49]. Therefore, the decision about HRT
use should be made with particular caution.
Breast feeding
Long-term breast feeding is indicated in all females
from families with HBC-ss, HBOC and HOC. It was
shown in BRCA1 carriers that breast feeding over 18
months, counting together all pregnancies, reduces
breast cancer risk – from 50-80% to 25-40% [50, 51].
Early delivery
Women from the general population who delivered
the first child before the age of 20 are at 50% lower
breast cancer risk than nulliparous women. This
observation was not confirmed in women with BRCA1
or  BRCA2 mutation [52]. However, taking into
consideration the fact that mutation carriers should
elect prophylactic oopherectomy at age 35-40, they
should not delay maternity significantly.
Chemoprevention
Tamoxifen
Literature data clearly indicate that tamoxifen reduces
by about 50% the risk of ER+ breast cancers. This effect
was observed in healthy women as well as in women
treated for breast cancer, where tamoxifen reduced the
risk of contralateral breast cancer. A protective effect of
tamoxifen was also observed in BRCA1 carriers in spite
of the fact that most cancers in these patients are ER-.
Such an effect of tamoxifen was observed in pre- and
postmenopausal women [53, 54]. According to present
data it is justified to propose 5 year chemoprevention with
tamoxifen to patients from families with HBC-ss, HBOC
and BRCA1 mutation carriers as well after exclusion of
all contraindications, especially related to clotting
problems and endometrial hypertrophy.
Selenium
Studies performed in our centre showed increased
mutagen sensitivity in BRCA1 carriers as measured with
the bleomycin test. This sensitivity may be normalized
with some selenium supplements [55]. Chemoprevention
with selenium has been observed to reduce cancer risk
in both humans and animals. This question should be
answered in BRCA1 carriers.
Adnexectomy
Both retrospective and prospective observations of
patients with BRCA1/2 mutations indicate that
prophylactic adnexectomy decreases the risk of
ovarian/peritoneal cancer to about 5% and breast
cancer to 30-40%. Application of adnexectomy
together with tamoxifen reduces breast cancer risk to
about 10% in BRCA1 carriers [14]. Therefore, in our
centre adnexectomy is recommended to all BRCA1/2
carriers aged over 35. This surgery is proposed to
women from families with HBC-ss, HBOC and HOC
but without detected BRCA1/BRCA2 mutation only if
other pathologies of the female genital tract were
recorded during control examinations. About 85% of
our patients accept this type of prophylaxis [56].H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 93
Mastectomy
The main target of prophylactic mastectomy is
reduction of breast cancer risk by removal of tissue at
risk. Single cases of breast cancer can develop from
the chest wall or from the axillary cave after
prophylactic mastectomy. It was noted, however, that
only 1% of patients from this group develop breast
cancer after prophylactic surgery [57]. It seams
reasonable to offer this type of surgery to highly
motivated patients with definitively diagnosed high
cancer risk, especially where tumoural and
mammographically dense breast glands are observed
which make early diagnosis extremely difficult. At
present, mastectomies with immediate reconstruction
are performed most frequently. This procedure ensures
a good cosmetic effect [58].
S Su ur rv ve ei il ll la an nc ce e
Surveillance in patients with HBC-ss, HBOC, HOC,
as well as in BRCA1/BRCA2 carriers is shown in Table 4.
This scheme is individualized for particular patients
with respect to age when particular examinations
should begin. In some families where breast cancer
was diagnosed before the age of 25 or ovarian cancer
before the age of 35 surveillance should begin 5 years
earlier than the age of diagnosis of cancer in this
family. In some cases, in addition to breast and ovary
investigations patients receive colonoscopy, gastroscopy
or evaluation of PSA level and prostate ultrasound if
in family members symptoms from the colon, gastric
or urinal tract are observed. However, it should be
noted that some control examinations have limited
value in detection of early cancers in BRCA1 carriers.
Ovarian cancer in clinical stage I is detected in only
10% of women with a BRCA1 mutation. On the other
hand, magnetic resonance imaging in diagnosis of
early breast cancers is introducing significant progress
[28, 59]. This examination allows detection of 77% of
breast cancers with diameter smaller than 1 cm and
in combination with ultrasound its sensitivity in detection
of early breast cancers rises to over 90% in BRCA1
carriers [59].
T Tr re ea at tm me en nt t
Existing data indicate that different rules should be
applied or at least considered as an option in treatment
of BRCA1 carriers. They include: 
• radical mastectomy instead of lumpectomy followed
by radiation therapy, because the risk of local
recurrence in the above procedures is 1% and 8%,
respectively (Narod SA, data not published);
• tamoxifen use in spite of ER- breast cancer, because
of 50% risk reduction of contralateral breast cancer
[53, 60];
• adnexectomy not only because of prophylaxis but
also because it was noted that 10-year survival is
twice as high in patients after this type of treatment
(Narod SA, data not published);
• breast cancer chemotherapy based on schemes
without taxanes [61]; treatment results based on
schemes with cis-platinum are very promising.
S Sy yn nd dr ro om me es s   a as ss so oc ci ia at te ed d   w wi it th h   g ge en ne et ti ic c
c ch ha an ng ge es s   o of f   m mo od de er ra at te el ly y   i in nc cr re ea as se ed d   r ri is sk k
The essential problem of clinical genetics is increased
hereditary predisposition to breast and ovarian cancer
in families with negative history of these cancers. Because
of the small number of family members in present
families, inheritance by the male line and not full
Hereditary breast and ovarian cancer
T Ta ab bl le e   4 4. .   Scheme of control examinations in families with high breast/ovarian cancer syndromes
O Or rg ga an n E Ex xa am mi in na at ti io on n A Ag ge e   o of f   b be eg gi in nn ni in ng g    F Fr re eq qu ue en nc cy y
( (y ye ea ar rs s) )
Breast self examination 20 every month
medical palpation  20-25 every 6 months
USG 25 every 6 months (6 months after mammography)
MRI 25 every 12 months
mammography 35 every 12 months
Female genital tract transvaginal ultrasound 30-35  every 12 months
CA 125 30-35  every 12 months (6 months after USG)H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 94
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penetrance, the influence of high risk genes like BRCA1/2
should be taken into consideration also in such families
(about 50% of BRCA1 mutation carriers with breast
cancer come from unaffected families [20]). However, a
clear majority of cancers in such families are associated
with other factors. The influence of multiple environmental
factors on cancer risk has already been documented in
the past. Recently, it has been shown that over 90% of
patients with breast cancer carry constitutional genetic
changes predisposing to development of this cancer [62].
In most cases, they are changes of moderately increased
risk. In that context we can suppose that unfavourable
environmental factors could lead to cancer development
only in patients with a particular genetic background. To
date the significance of several genetic changes has been
documented in the Polish population, which is the cause
for different options of clinical management for these
patients. It was found that constitutional changes in the
genes CHEK2 (1100delC, IVS2+1G>A, del5395,
I157T), NBS1 (657del5), NOD2 (3020insC), CDKN2A
(A148T), BRCA2 (5972C/T polymorphism) and CYP1B1
(homozygous GTC) are associated with increased breast
cancer risk in the Polish population [63, 64]. Carrier status
of protein truncated mutation in the CHEK2 gene
(1100delC, IVS2+1G>A, del5395) is associated with
about 2.2-fold increased breast cancer risk. This risk
concerns both young and older patients [63, 64].
Therefore, the control breast examination in this group
of patients starts from 25 years of age according to the
scheme shown in Table 5. Carriers of mutation CHEK2
I157T have increased cancer risk to a smaller degree
(1.4-fold higher than that in the general population).
Occurrence of breast cancer at young age is not
characteristic for this kind of mutation. However, patients
with this mutation demonstrate lobular type of breast
cancer much more often [65]. This cancer is difficult to
diagnose using mammography; therefore in this group
of patients magnetic resonance imaging (MRI) is
recommended from 40 years of age. Mutation 657del5
in the NBS1 gene is associated with about 3.5-fold
increased risk of breast cancer and this increase is the
strongest for patients below 40 years old [66] and with
positive cancer family history [67]. Mutation 3020insC
in the NOD2 gene is associated with breast cancer at
young age (OR=1.9). Characteristic for this mutation is
ductal breast cancer with a DCIS component [68]. This
kind of cancer is more often accompanied by multiple
calcifications; therefore mammography can be useful in
prophylaxis of patients with mutations in the NOD2 gene.
Polymorphism 5972C/T in the BRCA2 gene is also
associated with increased risk of breast cancer before 40
years of age (OR=1.4). The risk of cancer development
is higher in homozygotes (OR=4.8). This effect is observed
at both young and older age [69]. Increased risk is also
observed in carriers of CDKN2A A148T (OR=1.5) and
CYP1B1 (homozygote GTC) (OR=1.5). In these cases
an increased cancer risk at young age is observed.
Medical care for patients with genetic changes NBS1
(657del5),  NOD2 (3020insC), BRCA2 (5972C/T),
CDKN2A (A148T), and CYP1B1 (homozygote GTC)
begins at 25 years. Studies on the group of patients with
a family history of ovarian cancer allowed characteristic
clinical features of ovarian cancers without constitutional
mutations in genes BRCA1 and  BRCA2 to be
T Ta ab bl le e   5 5. .   Options of control examinations for carriers of moderate cancer risk gene mutations
O Or rg ga an n E Ex xa am mi in na at ti io on n A Ag ge e   o of f   b be eg gi in nn ni in ng g    F Fr re eq qu ue en nc cy y
( (y ye ea ar rs s) )
CHEK2 (1100delC, IVS2+1G>A,  self examination 20 every month
del5395), NBS1 (657del5), NOD2
medical palpation  20-25 every 6 months
(3020insC), CDKN2A (A148T)
USG 25 every 12 months
(6 months after mammography)
BRCA2 (5972C/T), CYP1B1 mammography 35 every 12 months
(homozygote GTC)
CHEK2 (I157T) self examination 20 every month
medical palpation  40 every 6 months
USG 40 every 12 months 
(6 months after mammography)
MRI 40 every 12 months
mammography 40 every 12 monthsH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2008; 6(2) 95
distinguished. Cancers in this group, unlike cases arising
on the basis of BRCA1 and BRCA2 mutation, are more
often diagnosed in postmenopausal (51-60 years)
women and also show lower morphological grading and
clinical staging. Analysis of the kind and location of
cancers among relatives of examined women showed
the increased frequency of ovarian cystadenoma
(cystadenoma ovarii) [70]. Cystadenomas of the ovary
are benign tumours which are able to, in some cases,
undergo malignant transformation into borderline
malignancy tumours, and sometimes even into cancer
(cystadenocarcinoma) [71, 72]. For development of this
kind of tumours the following constitutional changes can
predispose: NOD2 3020insC, CHEK2 I157T, CYP1B1
355T/T and DHCR7 W151X. In the group of “increased
risk” there are mainly women at reproductive age (≤50
years), who being carriers of at least one of the above-
mentioned molecular changes have over twofold
increased risk of the development of ovarian borderline
malignancy tumours (OR 2.26, P=0.0005). Therefore
for these women it should be considered to extend the
screening options with an additional control examination
of transvaginal USG (once a year) from 20-25 years.
Early tumour detection and its surgical resection can
prevent the development of ovarian cancer. Moreover,
in the case of the 355T/T variant CYP1B1 gene carriers
the screening options are extended with an additional
control examination for MRI of the breast (once a year)
for women aged 30-35 years, on account of almost 
3-fold increased risk of the development of cancer of this
organ (OR 2.75, P=0.03) [73, 74]. The preventive
screening is also recommended to first and second
degree female relatives of patients with ovarian
cystadenoma including:
• control examination by using transvaginal USG (once
a year), if in the patient ovarian borderline
malignancy tumour and CHEK2 I157T were detected; 
• control breast examination using MRI (once a year)
in the case of female relatives of patients with the
355T/T variant of the CYP1B1 gene and with benign
ovarian tumour.
Studies on genetic predisposition to breast cancer
or ovarian cystadenoma indicate the existence of
multigenetic relations causing high risk of cancer
development. It will probably require many years of
analysis to discover them.
S Su um mm ma ar ry y
Around 14 000 women develop breast or ovarian
cancer in Poland every year. Advances in clinical
genetics of cancers allow a significant number of these
cancers to be prevented. Additionally, patients of known
genetic background may be more effectively diagnosed
and treated due to the application of special, non-
standard systems of control examinations and treatment.
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